About AIGen Therapeutics
AIGen Therapeutics is a Healthcare company based in Gurugram (India) founded in 2019. It operates as an AI-driven company developing therapies for genetic and infectious diseases using advanced algorithms. It operates on a B2B model. AIGen Therapeutics offers products and services including AI Platform and Proprietary Datasets. Its focus areas include Biotechnology, AI Therapeutics, Drug Discovery and Genetic and Infectious Diseases. Its legal entity in India is Aigen Therapeutics Private Limited (U74994HR2019PTC080219). Similar companies include BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro and 4 more; 9 of its 9 listed similar companies have raised funding.
Company details
AIGen Therapeutics leverages proprietary AI algorithms and experimental datasets to create first-in-class therapies for deadly genetic and infectious diseases. The company combines AI with wet lab RD expertise to design biologics, antibodies, and peptides. It fosters clinical partnerships and analyzes vast datasets in genomics and proteomics for drug discovery. As a full-stack biotechnology startup, it focuses on innovative medicines through data analytics and supercomputing.
- Headquarters Gurugram, India
- SectorsHealthcare
- Website aigenthera.com
- Legal Name Aigen Therapeutics Private Limited
- Date of Incorporation 08 May, 2019
- Jurisdiction Gurgaon, Haryana, India
- Net Loss-₹4.2 Lakh
FY 2022 · 0% margin
- EBITDA-₹4.1 Lakh
FY 2022 · 0% margin
Associated legal entities of AIGen Therapeutics
AIGen Therapeutics operates through Aigen Therapeutics Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2022) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Aigen Therapeutics Private Limited CIN U74994HR2019PTC080219 | Active | 08 May 2019 | Gurgaon, Haryana | – | – | 2 | View details |
Products & Services of AIGen Therapeutics
AIGen Therapeutics offers a comprehensive portfolio of products and services, including AI Platform and Proprietary Datasets.
AI system for designing therapies using data analytics and algorithms.
Platform analyzing genomics and proteomics for therapeutic discoveries.
Board of directors of Aigen Therapeutics Private Limited (AIGen Therapeutics)
Aigen Therapeutics Private Limited is the primary company behind AIGen Therapeutics. The board of Aigen Therapeutics Private Limited currently have 2 directors; the longest-serving is Anup Kumar Gupta, appointed in 2019. 1 earlier director has ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Anup Kumar Gupta DIN 05138524 | Director | 08 May 2019 | 7 yrs 5 mo | Aigen Therapeutics Private Limited |
| Yash Pal Chaddah DIN 05139420 | Director | 08 May 2019 | 7 yrs 5 mo | Aigen Therapeutics Private Limited |
Financials of AIGen Therapeutics
Figures of Aigen Therapeutics Private Limited, the primary company behind AIGen Therapeutics, for FY 2022. Net loss was -₹4.2 Lakh (0% margin). EBITDA was -₹4.1 Lakh (0% margin).
- -₹4.2 LakhNet loss · 0% margin
- -₹4.1 LakhEBITDA · 0% margin
- ₹1 LakhPaid-up capital
Balance sheet, profit and loss, cash flow and ratios of Aigen Therapeutics Private Limited are on its company page.
Detailed financial statements for AIGen Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to AIGen Therapeutics
AIGen Therapeutics has 9 listed similar companies in our database, 9 of them funded. They include BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| chimerix.com | 2002 | Durham, United Kingdom | $95.23M | 72 | Antiviral oral therapeutics are developed for infectious diseases and cancers. |
Detailed similar companies of AIGen Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
10 companies that operate in the same segment as AIGen Therapeutics (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | 172 | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | 329 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about AIGen Therapeutics
AIGen Therapeutics was founded in 2019.
AIGen Therapeutics is headquartered in Gurugram, India. It is registered at Gurugram, Haryana, India.
AIGen Therapeutics leverages proprietary AI algorithms and experimental datasets to create first-in-class therapies for deadly genetic and infectious diseases. The company combines AI with wet lab RD expertise to design biologics, antibodies, and peptides. It fosters clinical partnerships and analyzes vast datasets in genomics and proteomics for drug discovery. As a full-stack biotechnology startup, it focuses on innovative medicines through data analytics and supercomputing.
AIGen Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
AIGen Therapeutics offers AI Platform and Proprietary Datasets.
AIGen Therapeutics operates through Aigen Therapeutics Private Limited.
The legal entities of AIGen Therapeutics currently have 2 directors, including Anup Kumar Gupta, Yash Pal Chaddah.